294 related articles for article (PubMed ID: 26808002)
1. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy.
Cai Y; Xu Y; Chan HF; Fang X; He C; Chen M
Mol Pharm; 2016 Mar; 13(3):699-709. PubMed ID: 26808002
[TBL] [Abstract][Full Text] [Related]
2. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
3. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
[TBL] [Abstract][Full Text] [Related]
4. Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro.
Wu F; Xue H; Li X; Diao W; Jiang B; Wang W; Yu W; Bai J; Wang Y; Lian B; Feng W; Sun T; Qu M; Zhao C; Wang Y; Wu J; Gao Z
Biomed Pharmacother; 2020 Nov; 131():110682. PubMed ID: 32947204
[TBL] [Abstract][Full Text] [Related]
5. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
Li J; Xu H; Ke X; Tian J
J Drug Target; 2012 Jun; 20(5):467-73. PubMed ID: 22577855
[TBL] [Abstract][Full Text] [Related]
6. Glycyrrhetinic acid as a hepatocyte targeting unit for an anticancer drug delivery system with enhanced cell type selectivity.
Singh H; Kim SJ; Kang DH; Kim HR; Sharma A; Kim WY; Kang C; Kim JS
Chem Commun (Camb); 2018 Oct; 54(87):12353-12356. PubMed ID: 30324188
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
[TBL] [Abstract][Full Text] [Related]
8. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
Lv Y; Li J; Chen H; Bai Y; Zhang L
Int J Nanomedicine; 2017; 12():4361-4370. PubMed ID: 28652738
[TBL] [Abstract][Full Text] [Related]
9. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
[TBL] [Abstract][Full Text] [Related]
11. Cleavable Multifunctional Targeting Mixed Micelles with Sequential pH-Triggered TAT Peptide Activation for Improved Antihepatocellular Carcinoma Efficacy.
Zhang J; Zheng Y; Xie X; Wang L; Su Z; Wang Y; Leong KW; Chen M
Mol Pharm; 2017 Nov; 14(11):3644-3659. PubMed ID: 28994600
[TBL] [Abstract][Full Text] [Related]
12. Cellular uptake mechanism and clearance kinetics of fluorescence-labeled glycyrrhetinic acid and glycyrrhetinic acid-modified liposome in hepatocellular carcinoma cells.
Sun Y; Lu J; Yan D; Shen L; Hu H; Chen D
Environ Toxicol Pharmacol; 2017 Jul; 53():46-56. PubMed ID: 28501784
[TBL] [Abstract][Full Text] [Related]
13. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
Xu Y; Wang M; Ning S; Yang Z; Zhou L; Xia X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296377
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
Sun Y; Dai C; Yin M; Lu J; Hu H; Chen D
Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
[TBL] [Abstract][Full Text] [Related]
15. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs.
Zhang L; Yao J; Zhou J; Wang T; Zhang Q
Int J Pharm; 2013 Jan; 441(1-2):654-64. PubMed ID: 23117024
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Asialoglycoprotein Receptor and Glycyrrhetinic Acid Receptor-Mediated and/or pH-Responsive Hepatocellular Carcinoma- Targeted Drug Delivery.
Li YL; Zhu XM; Liang H; Orvig C; Chen ZF
Curr Med Chem; 2021; 28(8):1508-1534. PubMed ID: 32368967
[TBL] [Abstract][Full Text] [Related]
17. Acid-sensitive polymeric vector targeting to hepatocarcinoma cells via glycyrrhetinic acid receptor-mediated endocytosis.
Yan T; Cheng J; Liu Z; Cheng F; Wei X; Huang Y; He J
Mater Sci Eng C Mater Biol Appl; 2018 Jun; 87():32-40. PubMed ID: 29549947
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
20. A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects.
Tian J; Wang L; Wang L; Ke X
Drug Deliv; 2014 Nov; 21(7):553-9. PubMed ID: 24215357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]